阿托伐他汀钙对脑梗死患者血清hs-CRP、TNF-α水平变化疗效分析

摘要

Objective To investigate the effect of atorvastatin calcium in the treatment of cerebral infarction and its onhighsensitive C-reactive protein (hs-CRP), tumor necrosis factor α (TNF-α). Methods Selected 122 patients with cerebral infarction treated in our hospital from January 2014 to January 2016, patients were randomly divided into observation group (n=69) and control group (n=53),the control group was given conventional treatment, the observation group was given atorvastatin calcium on the basis of conventional treatment,observed the National Institutes of Health Stroke Scale (NIHSS) and the daily life ability Barthel index (BI) score in the two groups after treatment,detected hs-CRP, TNF-α and carotid artery intima media thickness.Results After treatment, the NIHSS score of the observation group was (13.41 ±1.43), significantly lower than that of the control group (15.52±1.61) (P < 0.05), while the BI score was (43.82 ± 11.21), significantly higher than that of the control group (39.04±9.82 ) (P <0.05). The observation group after treatmenths-CRP and TNF-α were (6.71 ± 1.50) mg/L and (7.41 ± 2.08) ng/mL, significantly lower than the control group(10.02±1.78)mg/L and(10.10±2.32)ng/mL (P < 0.05). The observation group after treatment carotid artery intima media thickness was (1.10±0.27) mm, significantly lower than the control group (1.36±0.21)mm (P < 0.05). The incidence of adverse reactions in the observation group was 5.80%, the adverse reaction rate of the control group was 5.66%, the difference was not statistically significant. Conclusion Atorvastatin calcium has a good effect in the treatment of cerebral infarction, can reduce serum hs-CRP and TNF-α level, promote nerve function and daily life ability recovery, improve the thickness of the carotid artery.%目的 探讨阿托伐他汀钙在脑梗死治疗中的效果及对患者血清超敏C-反应蛋白(high sensitivity C-reactive protein,hs-CRP)、肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)的影响.方法 选取2014年1月~2016年1月在天津市泰达医院神经内科治疗的脑梗死患者122例,将患者随机分为观察组(n=69)和对照组(n=53),对照组给予常规治疗,观察组在常规治疗基础上给予阿托伐他汀钙,观察2组治疗后美国国立卫生研究院卒中量表(NIHSS)和日常生活能力Barthel指数(BI)评分,检测hs-CRP、TNF-α和颈动脉内膜厚度.结果 观察组治疗后NIHSS评分为(13.41±1.43)分,明显低于对照组的(15.52±1.61)分(P<0.05),而BI评分为(43.82±11.21)分,明显高于对照组的(39.04±9.82)分(P<0.05).观察组治疗后hs-CRP和TNF-α分别为(6.71±1.50)mg/mL、(7.41±2.08)ng/mL,明显低于对照组的(10.02±1.78)mg/mL、(10.10±2.32)ng/mL(P<0.05).观察组治疗后颈内动脉内膜厚度为(1.10±0.27)mm,明显低于对照组(1.36±0.21)mm(P<0.05);观察组不良反应发生率为5.80%,对照组不良反应发生率为5.66%,差异比较无统计学意义.结论 阿托伐他汀钙在脑梗死治疗中有较好的效果,能降低患者血清hs-CRP和TNF-α水平,促进神经功能以及日常生活能力的恢复,改善颈内动脉内膜厚度.